Some of those options, like monoclonal antibodies, are extremely expensive and hard to produce and distribute at scale, plus they only work early in the course of the disease. I'm not aware of any small-molecule drugs that have hopes of great efficacy on the horizon. You're not going to pump out 150K/day doses of MABs.

It really is vaccinate or risk dying. The other options are too expensive, too timing-dependent or too ineffective.